Loading clinical trials...
Loading clinical trials...
Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.
Gut microbiota as well as the signature of the 16S plasma bacterial DNA and bacterial metabolites of patients on the date of transplantation and during the first year after transplantation will be analyzed. The phenotype of the patients' T lymphocytes will be analyzed at the same time. These data will be correlated with the occurrence of acute cell rejection during the first year of transplantation
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Nephrologie transplantation CHRU Besançon
Besançon, France
Néphrologie, hémodialyse, aphérèses, transplantation rénale
La Tronche, France
Nephrologie transplantation CHRU Nantes
Nantes, France
Nephrologie transplantation CHU Saint Louis Paris
Paris, France
Nephrologie transplantation CHU Pitié Salpetriere Paris
Paris, France
Nephrologie hôpital Henri-Mondor
Paris, France
Nephrologie transplantation CHRU Poitiers
Poitiers, France
Nephrologie transplantation CHRU Toulouse
Toulouse, France
Nephrologie transplantation CHRU Tours
Tours, France
Start Date
October 7, 2021
Primary Completion Date
January 7, 2027
Completion Date
January 7, 2027
Last Updated
April 10, 2025
70
ESTIMATED participants
Belatacept Injection [Nulojix]
DRUG
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
NCT07006532
NCT04702022
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06825117